BioScience Managers invests in REX Bionics

Australian life sciences investment firm BioScience Managers has chosen a robotic exercise assist device (REX) as its first investment for the Biomedical Translation Fund.

The REX Bionics robotic device has been in development for over a decade and has racked up thousands of hours of user experience, helping to transform the lives of people with a range of mobility problems, stemming from spinal cord injuries, multiple sclerosis, brain injuries and neuromuscular conditions, BioScience Managers Managing Director Jeremy Curnock Cook said.

The latest version of REX, now available from the company’s purpose-built manufacturing facility, targets the rehabilitation market, and units are currently on trial in Australia and New Zealand, as well as rehabilitation centres of excellence in the UK and the USA.

Read more